scientific reports



OPEN Association between depression and anxiety on symptom and function after surgery for lumbar spinal stenosis

U. Held^{1,6}, J. M. Burgstaller^{2,3,6}, M. Deforth¹, J. Steurer², G. Pichierri^{2,3} & M. M. Wertli^{2,4,5}

Evidence on the role of depression and anxiety in patients undergoing surgical treatment for symptomatic degenerative lumbar spinal stenosis (DLSS) is conflicting. We aimed to assess the association between depression and anxiety with symptoms and function in patients undergoing surgery for DLSS. Included were patients with symptomatic DLSS participating in a prospective multicentre cohort study who underwent surgery and completed the 24-month follow-up. We used the hospital anxiety and depression scale (HADS) to assess depression/anxiety. We used mixed-effects models to quantify the impact on the primary outcome change in the spinal stenosis measure (SSM) symptoms/function subscale from baseline to 12- and 24-months. Logistic regression analysis was used to quantify the odds of the SSM to reach a minimal clinically important difference (MCID) at 24 months follow-up. The robustness of the results in the presence of unmeasured confounding was quantified using a benchmarking method based on a multiple linear model. Out of 401 patients 72 (17.95%) were depressed and 80 anxious (19.05%). Depression was associated with more symptoms $(\beta = 0.36, 95\% \text{ confidence interval (CI) } 0.20 \text{ to } 0.51, p < 0.001)$ and worse function $(\beta = 0.37, 95\% \text{ CI } 0.24)$ to 0.50, p < 0.001) at 12- and 24-months. Only the association between baseline depression and SSM symptoms/function was robust at 12 and 24 months. There was no evidence for baseline depression/ anxiety decreasing odds for a MCID in SSM symptoms and function over time. In patients undergoing surgery for symptomatic DLSS, preoperative depression but not anxiety was associated with more severe symptoms and disability at 12 and 24 months.

Abbreviations

- DLSS Degenerative lumbar spinal stenosis
- LSOS Lumbar Stenosis Outcome Study HADS Hospital anxiety and depression scale CIRS Cumulative illness rating scale SSM Spinal stenosis measure
- MCID Minimal clinically important difference

Degenerative lumbar spinal stenosis (DLSS) is a common indication for spine surgery in in the elderly^{1,2}. In symptomatic patients, the narrowing of spinal canal and compression of neural roots result in neurogenic claudication, a pain in the gluteal region and/or lower extremity during walking, which relieves through rest and lumbar flexion; with or without low back pain^{3,4}. Pain and functional limitations results in a strong negative influence on health-related quality of life⁵. In symptomatic patients, treatment options include watchful waiting, physiotherapy, pain medications, injection of analgesics and steroids, and decompression surgery⁶.

¹Department of Biostatistics at Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84, 8001 Zurich, Switzerland. ²Department of Internal Medicine, Horten Centre for Patient Oriented Research and Knowledge Transfer, University of Zurich, Pestalozzistrasse 24, 8032 Zurich, Switzerland. ³Institute of Primary Care, University and University Hospital Zurich, Pestalozzistrasse 24, 8032 Zurich, Switzerland. ⁴Department of General Internal Medicine, Kantonsspital Baden, Im Ergel 1, 5404 Baden, Switzerland. ⁵Division of General Internal Medicine, Bern University Hospital, University of Bern, Freiburgstrasse 16p, 3010 Bern, Switzerland. ⁶These authors contributed equally: U. Held and J. M. Burgstaller. [™]email: Maria.Wertli@insel.ch

Although surgery has been shown to be effective, not all patients will benefit from the treatment⁷. Approximately one-third of patients undergoing surgery will eventually not achieve a clinically relevant improvement⁷. Further, imaging studies in asymptomatic adults aged 60 years or older showed in up to 20% a stenosis without pain⁸. Various factors may influence treatment success in elderly patients. Age, sex, and comorbidities have been shown to result in longer hospital stay and more peri- and postoperative complications^{9–12}. Psychological factors such as depression and anxiety may be also relevant. Depression has been shown to negatively influence treatment efficacy in patients with DLSS¹³. The evidence on anxiety and the interaction between anxiety and depression is less well studied and conflicting^{14,15}.

The aim of this study is to evaluate whether depression and/or anxiety at baseline are associated with symptom severity and functional disability in patients with DLSS undergoing surgery. A novel methodological approach was used to assess the robustness of the results in the presence of unmeasured confounding¹⁶.

Methods

Data source and patient selection. Secondary analysis of patients included in a multicentre prospective cohort study conducted in eight hospitals in German-speaking Switzerland. The details of the study have been described previously^{3,17-19}. In summary, patients were included into the Lumbar Stenosis Outcome Study (LSOS) if they (1) were \geq 50 years old, (2) suffered from neurogenic claudication, (3) had a clinically and radiologically verified diagnosis of DLSS, (4) had a life-expectancy of > 1 year, (5) provided informed consent, and (6) follow-up assessment were feasible. Excluded were patients requiring urgent surgery, acute fractures or infection, excessive lumbar scoliosis (>15 degrees), verified peripheral arterial disease¹⁹. For the current study, we included patients who underwent surgery up to 6 months of study inclusion and completed a 24-month follow-up. Excluded were patients.

The study was approved by the ethical committee (canton Zurich, Switzerland, KEK-ZH-NR: 2010-0395/0). The study was reported according to the STROBE guidelines²⁰.

Surgical procedure. The choice of the surgical procedures was at the discretion of the treating physician. Procedures included decompression surgery alone or with fusion techniques. Decompression surgery consisted of a standard open posterior lumbar decompression of affected level(s) with or without decompression of the lateral recessus and the foramina where appropriate. Fusion surgery consisted of additional implantation of pedicle screws with rods, and intersomatic fusion and cage(s) at the affected level(s). All procedures were performed or supervised by senior orthopaedic/neurosurgeons (> 10 years of experience after board certification).


Depression and anxiety definition. Anxiety and depressive symptoms were assessed using the self-rated, validated, and reliable hospital anxiety and depression scale (HADS)²¹. The HADS consists of an anxiety and a depression subscale with a score-range of 0 (best) to 21 (worst) for each subscale^{22,23}. Patients were categorized as depressed if the score was ≥ 8 points on the HADS depression subscale (HADS-D)²¹. Anxiety was defined as ≥ 8 points on the HADS anxiety subscale (HADS-A)²¹. Sensitivity and specificity of a cut-off of ≥ 8 points for both HADS subscales to identify patients with depression/anxiety has been shown to be between 0.70 and 0.90²¹.

Outcomes. The primary outcomes were symptoms (pain) and physical function assessed using the spinal stenosis measure (SSM) symptoms and function subscale at 12 and 24 months. Secondary outcomes were meaningful clinically important difference (MCID) in the SSM symptoms and function at 24 months, complications, and reoperation rates. The SSM German version is a reliable and validated brief self-administered questionnaire (Supplementary Appendix 1)^{24,25}. The symptom subscale ranges from 1 to 5 points (best–worst) and the function subscale from 1 to 4 (best–worst). The MCID in the SSM symptoms subscale was a 0.48 point improvement (decrease) and in the SSM function subscale score 0.52 points^{24,25}. In patients with baseline values below the thresholds (SSM symptoms <1.48, SSM function <1.52), and remaining low SSM scores at all time points, an MCID of 1 was imputed at 24 months follow-up.

Sample size justification. The number of patients available for this study was large enough for fitting multiple linear mixed-effects regression models with a time trend, including the parameters of interest (depression and anxiety) as well as eight other baseline characteristics to adjust for confounding.

Confounder variables. Patients completed a set of self-reported questionnaires at baseline and additional information on comorbidities and smoking were collected during a structured interviews to complete the Cumulative illness rating scale (CIRS)²⁶. Each patient was asked whether he/she was currently smoking. In case a patient was a non-smoker, we additionally asked for smoking in the past. Smoker was defined as a patient that reported currently to smoke. Low back and buttock pain were assessed in self-reported questions at the baseline evaluation.

Statistical analysis. Descriptive statistics included mean and standard deviation (SD) (continuous/ordinal variables) and counts and percentages (categorical variables). Groups (depression/no depression and anxiety/ no anxiety) were compared with exploratory p-values from χ^2 and t tests. A predefined set of confounders¹⁸ was used including age, gender, body mass index (BMI) (\geq 25 kg/m²), civil risk (living alone, or single/divorced/ widowed and living in a nursing/residential home), duration of symptoms (>6 months), cumulative illness rating scale (CIRS), epidural injections within 90 days before baseline, and necessity of fusion surgery. Time was additionally included as a categorical variable, to account for overall trends at 12 and 24 months. We used multi-





ple linear mixed effects regression models with continuous SSM symptom and function scores (separately) over time. Repeated observations in SSM symptoms and function scores were captured in patient-specific random intercept terms. The effects of depression and anxiety were adjusted for overall change from baseline to 12 and 24 months in these outcomes. We evaluated whether there was the necessity for an interaction term of depression and anxiety, and we included the interaction term in the model, if the corresponding p-value of the interaction was < 0.05. Results were presented as beta-coefficients and corresponding 95% confidence intervals (95% CI).

For the binary outcomes MCID at 24 months for SSM symptom and SSM function, multiple logistic regression models (adjusted for the same confounders) were used to estimate odds ratios (OR) and the corresponding 95% CI. In all multiple regression models, missing values were excluded listwise.

Sensitivity analysis. A common concern in observational research is the presence of unmeasured confounding. Unmeasured confounding could affect the estimate of the variable of interest in principle in both directions (in- or decrease) of the estimated effect. In a first step, we adjusted the estimated effects of depression and anxiety for a set of eight pre-defined confounders. Because we could not exclude that other unmeasured confounders affect the results, we used a benchmarking method recently proposed by Cinelly and Hazlett¹⁶. We used a multiple linear model to assess the robustness of the estimated effects of baseline depression/anxiety on continuous outcomes SSM symptoms/function at 24 months. The idea was to quantify and assess visually how strong an unmeasured confounder would have to be to explain away the original effect¹⁶. In our study, the adjusted estimated effects of depression and anxiety from multiple linear mixed-effects regression models was benchmarked against gender, representing the most relevant confounder of clinical importance in this context, if there was strong evidence for an association. The proposed method used contour plots of the original estimate effects that are robust up to multiple times the benchmarking variable are considered less likely to be explained away by unmeasured confounding.

All analyses were performed with the statistical software R²⁷ in combination with dynamic reporting.

Results

Patient characteristics. Out of 451 patients who were eligible for the current study, 401 patients (88.91%) completed their 24-month follow-up assessment after surgery and were included in the analysis (Fig. 1). Reasons for missing follow-up evaluations included drop-out or moving to a residential home (n = 30, 6.65%), death (n = 10, 2.22%), and exclusion due to protocol violations (n = 10, 2.22%).

In total 50.37% were female, the mean age was 72.50 years (SD 8.41), mean BMI 27.30 kg/m² (SD 4.61), and symptom duration was > 6 months in 76.25% (Table 1). Compared to patients without depressive symptoms, depressed patients (n = 72, 17.95%) were more often women (63.89% vs. 47.42%) and had a higher mean score in

Variable	Overall	No depression [§]	Depression	Exploratory p-values	No anxiety*	Anxiety	Exploratory p-values
Number of patients (%)	401	329 (82.05)	72 (17.95)		321 (80.05)	80 (19.05)	
Age, mean (SD)	72.50 (8.41)	72.56 (8.19)	72.22 (9.44)	0.76	72.98 (8.23)	70.54 (8.92)	0.02
Female, n (%)	202 (50.37)	156 (47.42)	46 (63.89)	0.02	151 (47.04)	51 (63.75)	0.01
BMI kg/m ² , mean (SD)	27.30 (4.61)	27.41 (4.60)	26.78 (4.66)	0.29	27.40 (4.68)	26.92 (4.36)	0.41
BMI≥25 kg/m ² , n (%)	269 (67.08)	223 (67.78)	46 (63.89)	0.62	213 (66.36)	56 (70.00)	0.63
Civil risk*, n (%)	133 (33.17)	105 (31.91)	28 (38.89)	0.32	109 (33.96)	24 (30.00)	0.59
Compulsory education, n (%)	101 (25.19)	85 (25.84)	16 (22.22)	0.62	79 (24.61)	22 (27.50)	0.70
Back pain, n (%)	344 (86.22)	278 (85.02)	66 (91.67)	0.20	271 (84.95)	73 (91.25)	0.20
Buttocks pain, n (%)	317 (79.05)	257 (78.12)	60 (83.33)	0.41	246 (76.64)	71 (88.75)	0.03
Duration of symptoms > 6 months, n (%)	305 (76.25)	250 (76.22)	55 (76.39)	1.00	244 (76.25)	61 (76.25)	1.00
Problem getting better/worse during last 3 month	is, n (%)			0.16			0.03
Getting better	22 (5.50)	19 (5.79)	3 (4.17)		20 (6.25)	2 (2.50)	
Staying about the same	58 (14.50)	53 (16.16)	5 (6.94)		53 (16.56)	5 (6.25)	
Getting worse	318 (79.50)	254 (77.44)	64 (88.89)		246 (76.88)	72 (90.00)	
Don't know	2 (0.50)	2 (0.61)	0 (0.00)		1 (0.31)	1 (1.25)	
CIRS, mean (SD)	9.32 (3.93)	9.12 (3.97)	10.24 (3.67)	0.40	9.37 (4.03)	9.15 (3.55)	0.73
Diabetes, n (%)	47 (11.72)	36 (10.94)	11 (15.28)	0.73	39 (12.15)	8 (10.00)	0.19
Smoker, n (%)	64 (16.00)	51 (15.55)	13 (18.06)	< 0.001	47 (14.64)	17 (21.52)	< 0.001
HADS anxiety subscale, mean (SD)	4.55 (3.52)	3.69 (2.80)	8.49 (3.80)	< 0.001	3.19 (2.20)	10.03 (2.31)	< 0.001
HADS depression subscale, mean (SD)	4.67 (3.36)	3.44 (2.03)	10.31 (2.35)	< 0.001	3.81 (2.68)	8.15 (3.58)	< 0.001
Epidural injections within 90 days before baseline, n (%)	129 (32.17)	103 (31.31)	26 (36.11)	0.50	99 (30.84)	30 (37.50)	0.31
Surgery				0.18			0.09
Decompression surgery only, n (%)	307 (76.56)	247 (75.08)	60 (83.33)		252 (78.50)	55 (68.75)	
Decompression with fusion, n (%)	94 (23.44)	82 (24.92)	12 (16.67)		69 (21.50)	25 (31.25)	

Table 1. Baseline characteristics of the study population. *IQR* interquartile range, *CIRS* cumulative illness rating scale (range from 0 points (best) to 56 points (worst)), *HADS* hospital anxiety and depression scale (each subscale range from 0 points (best) to 21 points (worst)), *SSM* spinal stenosis outcome measure. [§]Depression defined as HADS depression subscale score ≥ 8 (score-range of 0 (best) to 21 (worst)). [‡]Anxiety defined as HADS anxiety subscale score ≥ 8 (score-range of 0 (best) to 21 (worst)). ^{*}Living alone, or single/divorced/ widowed and living in a nursing/residential home. χ^2 and t-tests were used for group comparison.

the HADS anxiety subscale (8.49 vs. 3.69). Compared to patients without anxiety, patients with anxiety (n = 80, 19.05%) were younger (mean age 70.54 vs. 72.98 years), more likely female (63.75% vs. 47.04%), had more buttocks pain (88.75% vs 76.64%), complained about more worsening symptoms during the last three months (90.0% vs. 76.88%) and had higher mean score in the HADS depression subscale (8.15 vs. 3.81). Although not statistically significant, the proportion of decompression surgery only was higher in patients with depression compared to non-depressed patients. The proportion of fusion surgery was somewhat higher in patients with anxiety (31.25% vs. 21.50%, p = 0.09).

Surgical treatment types, surgical complications, and reoperations. Surgical procedures included decompression alone (n = 307, 76.56%) and decompression and fusion surgery (n = 94, 23.44%). Table 2 summarizes intra- and postoperative complications and reoperations. Intra- and postoperative complications occurred in 70 (17.46%) index operations with dural tear (6.22%) being the most common intraoperative complication. There was no difference in complication rates, reoperation rates, and reasons for reoperation in patients with/ without depression and anxiety (Table 2).

Improvement in symptoms and function between baseline and 24-month. Table 3 summarizes the mean SSM symptoms and function scores at baseline, 12- and 24-months follow-up. Depressed patients expressed higher SSM symptoms compared to patients with no depression (3.39 vs. 3.08, p < 0.001) and function scores (2.55 vs. 2.18, p < 0.001). Baseline anxiety was associated with higher SSM symptoms (3.42 vs. 3.07, p < 0.001) and function scores (2.51 vs. 2.18, p < 0.001).

On average, patients improved over time in both outcome scores (Tables 3, 4). Baseline depression was associated with worse SSM symptoms (β =0.36, 95% CI 0.20 to 0.51, p<0.001, Table 4a) and SSM function (β =0.37, 95% CI 0.24 to 0.50, p<0.001, Table 4b) scores at 24-month follow-up. Baseline anxiety was associated with worse SSM symptoms (β =0.18, 95% CI 0.03 to 0.33, p=0.02) without evidence for an association with SSM function (β =0.03, 95% CI -0.09 to 0.16, p=0.63). Whereas each effect size was smaller than the 0.48 points for SSM symptoms and 0.52 points for SSM function score, effects of anxiety and depression combined were clinically relevant. There was no significant interaction between anxiety and depression for SSM symptoms (p=0.48) and function (p=0.47).

Variable	Overall	No depression	Depression	Exploratory p-values	No anxiety	Anxiety	Exploratory p-values
n	401	329	72		321	80	
Complications				1		1	
Intraoperative bleeding	4 (1.00)	3 (0.91)	1 (1.39)	1.00	4 (1.25)	0 (0.00)	0.71
Intraoperative dural tear	25 (6.22)	24 (7.29)	1 (1.39)	0.11	25 (7.79)	0 (0.00)	0.02
Postoperative wound infection	5 (1.24)	3 (0.91)	2 (2.78)	0.48	3 (0.93)	2 (2.50)	0.57
Postoperative osse- ous infection	1 (0.25)	1 (0.30)	0 (0.00)	1.00	1 (0.31)	0 (0.00)	1.00
Postoperative other*	35 (8.71)	26 (7.90)	9 (12.50)	0.31	26 (8.10)	9 (11.25)	0.50
Number of reopera- tions: n	53	34	19		37	16	
1 reoperation, patients: n (%)	42 (79.25)	28 (82.35)	14 (73.68)	0.37	30 (81.08)	12 (75.00)	0.63
2 reoperations, patients: n (%)	10 (18.87)	6 (17.65)	4 (21.05)		6 (16.22)	4 (25.00)	
3 reoperations, patients: n (%)	1 (1.89)	0 (0.00)	1 (5.26)		1 (2.70)	0 (0.00)	
Type of reoperation: fusion	32 (60.38)	19 (55.88)	13 (68.42)	0.55	21 (56.76)	11 (68.75)	0.61
Indication: restenosis	38 (71.70)	22 (64.71)	16 (84.21)	0.23	26 (70.27)	12 (75.00)	0.99
Indication: infection	1 (1.89)	1 (2.94)	0 (0.00)	1.00	0 (0.00)	1 (6.25)	0.66
During the 1. year	36 (67.92)	21 (61.76)	15 (78.95)	0.33	26 (70.27)	10 (62.50)	0.81
During the 2. year	16 (30.19)	12 (35.29)	4 (21.05)	0.44	10 (27.03)	6 (37.50)	0.66
During the 3. year	1 (1.89)	1 (2.94)	0 (0.00)	1.00	1 (2.70)	0 (0.00)	1.00
Median days baseline operation to 1. reop- eration, (IQR)	199.50 [92.25, 469.75]	213.00 [56.00, 483.50]	193.50 [152.50, 415.00]	0.94	190.00 [56.00, 441.25]	369.50 [153.50, 473.25]	0.20
Median days 1. reoperation to 2. reoperation, (IQR)	200.50 [81.75, 322.75]	207.00 [113.00, 374.50]	149.00 [12.50, 294.50]	0.29	288.50 [159.75, 374.50]	63.50 [12.50, 166.25]	0.14
Median days 2. Reoperation to 3. reoperation, (IQR)	86.00 [86.00, 86.00]	NA [NA, NA]	86.00 [86.00, 86.00]	NA	86.00 [86.00, 86.00]	NA [NA, NA]	NA

Table 2. Surgical complications, and reoperations. NA not applicable. *Example, urosepsis, hemorrhage, wound healing deficit.

Variable	Overall	No depression	Depression	No anxiety	Anxiety			
SSM symptoms, mean (SD)								
Baseline	3.14 (0.59)	3.08 (0.58)	3.39 (0.59)	3.07 (0.59)	3.42 (0.52)			
12-months	2.10 (0.80)	1.99 (0.74)	2.61 (0.84)	2.02 (0.77)	2.38 (0.85)			
24-months	2.15 (0.84)	2.05 (0.82)	2.63 (0.77)	2.09 (0.84)	2.41 (0.81)			
SSM function, mean (SD)								
Baseline	2.24 (0.66)	2.18 (0.64)	2.55 (0.64)	2.18 (0.66)	2.51 (0.58)			
12-months	1.52 (0.60)	1.43 (0.53)	1.91 (0.73)	1.49 (0.59)	1.64 (0.64)			
24-months	1.55 (0.62)	1.46 (0.56)	1.93 (0.70)	1.52 (0.62)	1.64 (0.61)			

Table 3. Symptoms and function at baseline and follow-up. SSM spinal stenosis outcome measure.

.....

Sensitivity analysis. The sensitivity analysis was performed for depression, as there was strong evidence for an association with SSM symptoms and SSM function. The sensitivity analysis revealed that the estimated effect of depression on SSM symptoms and SSM function was robust even if an unmeasured confounder of the magnitude of at least 10 times gender was present in our study (Fig. 2a,b).

Clinical relevance of depression and anxiety. The number of patients with clinically meaningful improvement (MCID) in SSM symptoms was 280 (69.83%; depression 63.89%, no depression 71.12%, anxiety 68.75%, and no anxiety 70.09%) over 2 years follow-up. The corresponding numbers for patients with MCID in SSM function were 254 (63.34%; depression 56.94%, no depression 64.74%, anxiety 67.50%, and no anxiety

Intercept 2.28 1.76 2.81 <0.001	Variable	Estimate	Lower bound of 95% CI	Upper bound of 95% CI	p-value
Let 1 Control Contro Control Control Contro Control Control Control <thcontro< th=""> <thcontro< th=""> <thcont< td=""><td>(A) SSM symptoms</td><td></td><td></td><td></td><td></td></thcont<></thcontro<></thcontro<>	(A) SSM symptoms				
Anxiety10.180.030.330.02Time 12 months follow-up -1.04 -1.12 -0.96 <0.001	(Intercept)	2.28	1.76	2.81	< 0.001
Time 12 months follow-up-1.04-1.12-0.96<0.001Time 24 months follow-up-0.99-1.07-0.91<0.001	Depression [§]	0.36	0.20	0.51	< 0.001
Time 24 months follow-up -0.99 -1.07 -0.91 <0.001 Age 0.003 -0.004 0.01 0.34 Female 0.20 0.08 0.32 0.001 BMI ≥ 25 kg/m² 0.14 0.02 0.25 0.02 Civil risk* -0.02 -0.15 0.10 0.71 Duration of symptoms > 6 months 0.07 -0.06 0.20 0.28 CIRS 0.03 0.02 0.05 <0.001 Epidural injections within 90 days before baseline -0.02 -0.13 0.10 0.76 Fusion surgery -0.06 -0.19 0.07 0.39 (Intercept) 1.48 1.05 1.92 <0.001 Depression ⁵ 0.37 0.24 0.50 <0.001 Anxiety ⁴ 0.03 -0.09 0.16 0.63 Time 12 months follow-up -0.73 -0.79 -0.66 <0.001 Age 0.005 -0.001 0.01 0.12 Female 0.19 0.10 0.29 <0.001 BMI ≥ 25 kg/m² 0.19 0.10 0.29 <0.001 Civil risk* -0.03 -0.14 0.07 0.54 Duration of symptoms > 6 months 0.01 -0.10 0.11 0.91 CiVI risk* 0.02 0.01 0.03 0.01 Epidural injections within 90 days before baseline 0.03 -0.07 0.13 0.55	Anxiety [‡]	0.18	0.03	0.33	0.02
Age0.003-0.0040.010.34Female0.200.080.320.001BM1 \geq 25 kg/m²0.140.020.250.02Civil risk*-0.02-0.150.100.71Duration of symptoms > 6 months0.07-0.060.200.28CIRS0.030.020.05<0.001	Time 12 months follow-up	- 1.04	-1.12	- 0.96	< 0.001
ooooFemale0.200.080.320.001BM1 ≥ 25 kg/m²0.140.020.250.02Civil risk*-0.02-0.150.100.71Duration of symptoms > 6 months0.07-0.060.200.28CIRS0.030.020.05<0.001	Time 24 months follow-up	- 0.99	-1.07	-0.91	< 0.001
Number BMI $\geq 25 \text{ kg/m}^2$ Number 0.14Number 0.02Number 0.25Number 0.02Givil risk* -0.02 -0.15 0.100.71Duration of symptoms > 6 months0.07 -0.06 0.200.28CIRS0.030.020.05<0.001	Age	0.003	-0.004	0.01	0.34
Civil risk* -0.02 -0.15 0.10 0.71 Duration of symptoms > 6 months 0.07 -0.06 0.20 0.28 CIRS 0.03 0.02 0.05 < 0.001 Epidural injections within 90 days before baseline -0.02 -0.13 0.10 0.76 Fusion surgery -0.06 -0.19 0.07 0.39 (B) SSM function (Intercept) 1.48 1.05 1.92 < 0.001 Depression ⁵ 0.37 0.24 0.50 < 0.001 Anxiety [‡] 0.03 -0.09 0.16 0.63 Time 12 months follow-up -0.73 -0.79 -0.66 < 0.001 Time 24 months follow-up -0.70 -0.76 -0.63 < 0.001 Age 0.09 0.10 0.29 < 0.001 BMI $\ge 25 \text{ kg/m^2}$ 0.19 0.10 0.29 < 0.001 Civil risk* -0.03 -0.14 0.07 0.54	Female	0.20	0.08	0.32	0.001
International control Internatind contradity control Internatind control	BMI \ge 25 kg/m ²	0.14	0.02	0.25	0.02
CIRS0.030.020.05<0.001Epidural injections within 90 days before baseline -0.02 -0.13 0.100.76Fusion surgery -0.06 -0.19 0.070.39(B) SSM function(Intercept)1.481.051.92<0.001	Civil risk*	- 0.02	-0.15	0.10	0.71
Epidural injections within 90 days before baseline -0.02 -0.13 0.10 0.76 Fusion surgery -0.06 -0.19 0.07 0.39 (B) SSM function (Intercept) 1.48 1.05 1.92 <0.001 Depression ⁶ 0.37 0.24 0.50 <0.001 Anxiety ⁴ 0.03 -0.09 0.16 0.63 Time 12 months follow-up -0.73 -0.79 -0.66 <0.001 Time 24 months follow-up -0.70 -0.76 -0.63 <0.001 Age 0.095 -0.001 0.01 0.12 <0.001 BMI ≥ 25 kg/m ² 0.19 0.10 0.29 <0.001 0.54 Duration of symptoms > 6 months 0.01 -0.14 0.07 0.54 0.91 0.91 0.91 0.91 0.91 0.91 0.91 0.91 0.91 0.91 0.91 0.91 0.91 0.91 0.91 0.91 0.91	Duration of symptoms > 6 months	0.07	-0.06	0.20	0.28
Fusion surgery -0.06 -0.19 0.07 0.39 (B) SSM function(Intercept)1.481.051.92 <0.001 Depression§0.370.240.50 <0.001 Anxiety [‡] 0.03 -0.09 0.160.63Time 12 months follow-up -0.73 -0.79 -0.66 <0.001 Age0.005 -0.001 0.010.12Female0.190.100.29 <0.001 BMI ≥ 25 kg/m²0.010.010.54Duration of symptoms > 6 months0.01 -0.10 0.110.91CIRS0.020.010.030.01Epidural injections within 90 days before baseline0.03 -0.07 0.130.55	CIRS	0.03	0.02	0.05	< 0.001
(B) SSM function 1.48 1.05 1.92 <0.001 Depression [§] 0.37 0.24 0.50 <0.001	Epidural injections within 90 days before baseline	-0.02	-0.13	0.10	0.76
I.48 1.05 1.92 <0.001 Depression [§] 0.37 0.24 0.50 <0.001	Fusion surgery	-0.06	-0.19	0.07	0.39
Depression 6 0.370.240.50<0.001Anxiety ‡ 0.03-0.090.160.63Time 12 months follow-up-0.73-0.79-0.66<0.001	(B) SSM function		1	1	
Anxiety [‡] 0.03 -0.09 0.160.63Time 12 months follow-up -0.73 -0.79 -0.66 <0.001 Time 24 months follow-up -0.70 -0.76 -0.63 <0.001 Age0.005 -0.001 0.01 0.12 Female0.190.100.29 <0.001 BMI ≥ 25 kg/m ² 0.190.100.29 <0.001 Civil risk* -0.03 -0.14 0.07 0.54 Duration of symptoms > 6 months0.01 -0.10 0.11 0.91 Epidural injections within 90 days before baseline 0.03 -0.07 0.13 0.55	(Intercept)	1.48	1.05	1.92	< 0.001
Time 12 months follow-up -0.73 -0.79 -0.66 <0.001 Time 24 months follow-up -0.70 -0.76 -0.63 <0.001 Age 0.005 -0.001 0.01 0.12 Female 0.19 0.10 0.29 <0.001 BMI ≥ 25 kg/m² 0.19 0.10 0.29 <0.001 Civil risk* -0.03 -0.14 0.07 0.54 Duration of symptoms > 6 months 0.01 -0.10 0.11 0.91 CIRS 0.02 0.01 0.03 0.01 Epidural injections within 90 days before baseline 0.03 -0.07 0.13 0.55	Depression [§]	0.37	0.24	0.50	< 0.001
Image 24 months follow-up -0.70 -0.76 -0.63 <0.001 Age 0.005 -0.001 0.01 0.12 Female 0.19 0.10 0.29 <0.001 BMI ≥ 25 kg/m² 0.19 0.10 0.29 <0.001 Civil risk* -0.03 -0.14 0.07 0.54 Duration of symptoms > 6 months 0.01 -0.10 0.11 0.91 CIRS 0.02 0.01 0.03 0.01 Epidural injections within 90 days before baseline 0.03 -0.07 0.13 0.55	Anxiety [‡]	0.03	-0.09	0.16	0.63
Age0.005 -0.001 0.010.12Female0.190.100.29 $<$ 0.001BMI ≥ 25 kg/m²0.190.100.29 $<$ 0.001Civil risk* -0.03 -0.14 0.070.54Duration of symptoms > 6 months0.01 -0.10 0.110.91CIRS0.020.010.030.01Epidural injections within 90 days before baseline0.03 -0.07 0.130.55	Time 12 months follow-up	-0.73	-0.79	-0.66	< 0.001
B0.190.100.29<0.001BMI \geq 25 kg/m²0.190.100.29<0.001	Time 24 months follow-up	-0.70	-0.76	-0.63	< 0.001
BMI $\geq 25 \text{ kg/m}^2$ 0.19 0.10 0.29 <0.001 Civil risk* -0.03 -0.14 0.07 0.54 Duration of symptoms > 6 months 0.01 -0.10 0.11 0.91 CIRS 0.02 0.01 0.03 0.01 Epidural injections within 90 days before baseline 0.03 -0.07 0.13 0.55	Age	0.005	-0.001	0.01	0.12
Civil risk* -0.03 -0.14 0.07 0.54 Duration of symptoms>6 months 0.01 -0.10 0.11 0.91 CIRS 0.02 0.01 0.03 0.01 Epidural injections within 90 days before baseline 0.03 -0.07 0.13 0.55	Female	0.19	0.10	0.29	< 0.001
Duration of symptoms>6 months 0.01 -0.10 0.11 0.91 CIRS 0.02 0.01 0.03 0.01 Epidural injections within 90 days before baseline 0.03 -0.07 0.13 0.55	BMI \ge 25 kg/m ²	0.19	0.10	0.29	< 0.001
CIRS 0.02 0.01 0.03 0.01 Epidural injections within 90 days before baseline 0.03 -0.07 0.13 0.55	Civil risk*	- 0.03	-0.14	0.07	0.54
Epidural injections within 90 days before baseline0.03-0.070.130.55	Duration of symptoms > 6 months	0.01	-0.10	0.11	0.91
	CIRS	0.02	0.01	0.03	0.01
Fusion surgery -0.12 -0.23 -0.01 0.03	Epidural injections within 90 days before baseline	0.03	-0.07	0.13	0.55
	Fusion surgery	-0.12	-0.23	-0.01	0.03

Table 4. Summary of the multiple linear mixed effects regression models for SSM symptom and function at 12 and 24 months in patients with depression and anxiety. A negative value corresponds to reduction of symptom severity/functional disability. *CIRS* cumulative illness rating scale (range from 0 points (best) to 56 points (worst)). [§]Depression defined as HADS depression subscale score ≥ 8 (score-range of 0 (best) to 21 (worst)). ^{*}Anxiety defined as HADS anxiety subscale score ≥ 8 (score-range of 0 (best) to 21 (worst)). *Living alone, or single/divorced/widowed and living in a nursing/residential home. Significance values are given in bold.

62.31%). There was no evidence that depression was associated with decreased odds for a MCID in SSM symptoms (OR 0.70, 95% CI 0.37 to 1.34, p = 0.28) and function (OR 0.59, 95% CI 0.32 to 1.11, p = 0.10) at 24-month follow-up. There was also no evidence that anxiety was associated with a decreased odds for a MCID in SSM symptoms (OR 1.01, 95% CI 0.54 to 1.96, p = 0.97) and SSM function (OR 1.47, 95% CI 0.80 to 2.79, p = 0.22) scores at 24-month follow-up (Table 5).

Discussion

In this study of 401 patients undergoing surgery for symptomatic DLSS, we found a robust association between baseline depression with more severe symptoms and worse function even after accounting for the potential presence of strong unmeasured confounding. Although the effect of anxiety alone was clinically not relevant, baseline depression and anxiety combined were associated with a clinically relevant increase in the severity of symptoms over the study period. Baseline depression and anxiety did not reduce the odds for a clinical meaningful improvement in symptoms and function scores and were not associated with complication rates and reoperation.

Results in the light of existing literature. The results from our study expands on the conclusion of a systematic review published in 2014¹³. Although our study supports the authors conclusion that depression is a prognostic indicator in patients undergoing surgery for lumbar spinal stenosis¹³ for symptoms and function, depression did not result in a reduced odds for a clinical meaningful improvement after surgery. Lebow et al.²⁸ argued that pain from disc herniation might contribute to preoperative depression and anxiety and that discectomy improves mental health and well-being during the postoperative period over months with improvement in anxiety and depression. Three studies showed level of depression measured preoperatively did not predict the surgical outcome^{15,28,29} and that depression improved postoperatively in patients with a favorable outcome and did not improve in patients with a poor treatment outcome, suggesting that psychological disorders may be the result of DLSS related complaints^{29,30}. However, other studies found preoperative depression to be associated




Figure 2. (a) Contour plot of robustness of depression for SSM symptoms. The partial R^2 gives the percentage of variation in a multiple linear model that cannot be explained by the confounders. The unadjusted estimate 0.41 represents the estimate for depression in a multiple linear model with SSM symptoms as outcome, and with the confounders age, gender female, $BMI \ge 25$, civil risk, duration of symptoms > 6 months, CIRS, epidural injections within 90 days before baseline, and necessity of fusion surgery. The estimate of 0.36 represents the estimate for depression on SSM symptoms, if there was an unmeasured confounders with the strength of association of five times female gender present. Accordingly, the estimate of 0.31 shows the estimate for depression on SSM symptom if there was an unmeasured confounder with the strength of association of ten times gender female present. The sensitivity analysis shows that even in the presence of a strong unmeasured confounder, the estimate of depression on SSM symptom would remain robust. (b) Contour plot of robustness of depression for SSM function. The partial R2 gives the percentage of variation in a multiple linear model that cannot be explained by the confounders. The unadjusted estimate 0.39 represents the estimate for depression in a multiple linear model with SSM function as outcome, and with the confounders age, gender female, $BMI \ge 25$, civil risk, duration of symptoms > 6 months, CIRS, epidural injections within 90 days before baseline, and necessity of fusion surgery. The estimate of 0.35 represents the estimate for depression on SSM function, if there was an unmeasured confounders with the strength of association of five times female gender present. Accordingly, the estimate of 0.31 shows the estimate for depression on SSM function if there was an unmeasured confounder with the strength of association of ten times gender female present. The sensitivity analysis shows that even in the presence of a strong unmeasured confounder, the estimate of depression on SSM function would remain robust.

with poorer life satisfaction after surgery³¹ and poorer treatment outcome (symptom severity, disability and walking capacity) after surgery^{31,32}. Whether depression alone or as a result of a general life-dissatisfaction, as suggested by a study following patients over 10 years after surgery for DLSS³³, warrants further investigation to elucidate whether preoperative depression should be addressed as a modifiable factor.

A systematic review concluded that anxiety and catastrophizing may be a relevant and modifiable factor to consider, in particular, in musculoskeletal surgery³⁴. In one study preoperative anxiety was associated with postoperative anxiety and physical complaints after lumbar spinal surgery³⁵. Pain related anxiety and avoidance behavior are physiological responses after an acute incidence. However, over time avoidance may result in disuse and disability and may increase the disease burden^{36,37}. Therefore, anxiety and avoidance may be potentially modifiable coping styles^{38–40} and relevant to consider after spine surgery. Indeed, patients with persistent fear avoidance beliefs after decompression surgery for DLSS reported poorer treatment outcome after 1 year than patients with decreased or no fear avoidance beliefs after surgery^{41,42}. In the current study, we observed an additive effect of anxiety to depression which reached clinical relevance for symptoms which may warrant further studies.

Implications for research. Depression and anxiety may be relevant and modifiable factors to consider during the postoperative phase and should be further studied. In particular, in patients with persistent depression despite improvement after surgery, concomitant psychological interventions should be studied. Further, the importance of pre- and perioperative stress on postoperative complications is not well understood. Starkweather et al.⁴³ showed that psychological stress had an immunosuppressive effect that may result in an increased risk for complications.

Variable	OR**	Lower bound of 95% CI	Upper bound of 95% CI	p
(A) SSM symptoms				
Depression [§]	0.70	0.37	1.34	0.28
Anxiety [‡]	1.01	0.54	1.96	0.97
Age	0.97	0.94	0.10	0.02
Female	1.00	0.61	1.66	1.00
BMI \ge 25 kg/m ²	0.77	0.46	1.27	0.31
Civil risk*	0.76	0.45	1.28	0.29
Duration of symptoms > 6 months	0.55	0.30	0.97	0.04
CIRS	0.98	0.92	1.04	0.44
Epidural injections within 90 days before baseline	1.69	1.02	2.85	0.05
Fusion surgery	1.02	0.58	1.81	0.96
(B) SSM function				
Depression [§]	0.59	0.32	1.11	0.10
Anxiety [‡]	1.47	0.80	2.79	0.22
Age	0.97	0.94	1.00	0.05
Female	0.87	0.54	1.39	0.55
BMI \ge 25 kg/m ²	0.70	0.44	1.12	0.14
Civil risk*	0.94	0.57	1.56	0.81
Duration of symptoms > 6 months	0.47	0.27	0.82	0.01
CIRS	0.95	0.90	1.00	0.07
Epidural injections within 90 days before baseline	1.56	0.98	2.53	0.07
Fusion surgery	0.84	0.50	1.43	0.52

Table 5. Summary of the multiple logistic regression models for minimal clinical important difference(MCID) in the SSM symptoms and function at 24 months in patients with depression, anxiety. §Depressiondefined as HADS depression subscale score ≥ 8 (score-range of 0 (best) to 21 (worst)). *Anxiety defined asHADS anxiety subscale score ≥ 8 (score-range of 0 (best) to 21 (worst)). *Living alone, or single/divorced/widowed and living in a nursing/residential home. **A value smaller than 1 corresponds to a reduced chanceto achieve minimal important difference of SSM symptoms/function subscale. Significance values are given inbold.

Implications for clinical practice. Although patients with preoperative depression and anxiety may report more symptoms after a 2-year follow-up, they are equally likely to experience a clinical meaningful improvement as patients without depression or anxiety.

Strength and limitations. A strength of the study include the large number of patients undergoing in surgery for symptomatic DLSS, the prospective recording of known prognostic factors, and the use of a novel method to benchmark the estimated effect of depression against the clinically most relevant confounder gender. A strength of our study is that we used new methods to assess the relevance of the findings accounting for unmeasured confounding. There are several limitations to discuss. First, depression and anxiety were based on self-reported measures (the validated HADS questionnaire) and we had no information on the clinical diagnosis and treatment of depression. Therefore, we were not able to determine the severity and nature of depression and anxiety. Further, we do not know whether some patients received treatment for depressive symptoms that may influent treatment outcome. Second, we did not collect information on anxiety and depression/anxiety, and outcome.

Conclusion

In patients undergoing surgery for symptomatic DLSS, we observed a robust association between preoperative depression and more symptoms and disability at 12- and 24-months. Anxiety was associated with more symptoms at 12- and 24-months but the effect was small. Both, baseline depression and anxiety did not influence the odds for clinically meaningful improvement in symptoms and function scores.

Received: 5 June 2021; Accepted: 31 January 2022 Published online: 18 February 2022

References

1. Deyo, R. A. Treatment of lumbar spinal stenosis: A balancing act. *Spine J.* **10**, 625–627. https://doi.org/10.1016/j.spinee.2010.05. 006 (2010).

- Ravindra, V. M. et al. Degenerative lumbar spine disease: Estimating global incidence and worldwide volume. Glob. Spine J. 8, 784–794. https://doi.org/10.1177/2192568218770769 (2018).
- 3. Steurer, J. et al. LumbSten: The lumbar spinal stenosis outcome study. BMC Musculoskelet. Disord. 11, 254 (2010).
- 4. Weinstein, J. N. *et al.* Surgical versus nonoperative treatment for lumbar spinal stenosis four-year results of the spine patient outcomes research trial. *Spine* **35**, 1329–1338. https://doi.org/10.1097/BRS.0b013e3181e0f04d (2010).
- Otani, K. *et al.* Lumbar spinal stenosis has a negative impact on quality of life compared with other comorbidities: An epidemiological cross-sectional study of 1862 community-dwelling individuals. *Sci. World J.* 2013, 590652. https://doi.org/10.1155/2013/ 590652 (2013).
- Kreiner, D. S. et al. An evidence-based clinical guideline for the diagnosis and treatment of lumbar disc herniation with radiculopathy. Spine J. 14, 180–191. https://doi.org/10.1016/j.spinee.2013.08.003 (2014).
- 7. Wertli, M. M. *et al.* A comparison between different outcome measures based on "meaningful important differences" in patients with lumbar spinal stenosis. *Eur. Spine J.* 26, 450–461. https://doi.org/10.1007/s00586-016-4587-0 (2017).
- Boden, S. D., Davis, D. O., Dina, T. S., Patronas, N. J. & Wiesel, S. W. Abnormal magnetic-resonance scans of the lumbar spine in asymptomatic subjects. A prospective investigation. J. Bone Jt. Surg. Am. 72, 403–408 (1990).
- 9. Marengoni, A. *et al.* Coexisting chronic conditions in the older population: Variation by health indicators. *Eur. J. Intern. Med.* **31**, 29–34. https://doi.org/10.1016/j.ejim.2016.02.014 (2016).
- 10. Bouras, T. *et al.* Predictors of long-term outcome in an elderly group after laminectomy for lumbar stenosis. *J. Neurosurg. Spine* 13, 329–334. https://doi.org/10.3171/2010.3.SPINE09487 (2010).
- Basques, B. A., Varthi, A. G., Golinvaux, N. S., Bohl, D. D. & Grauer, J. N. Patient characteristics associated with increased postoperative length of stay and readmission after elective laminectomy for lumbar spinal stenosis. *Spine* 39, 833–840. https://doi.org/ 10.1097/BRS.00000000000276 (2014).
- Choi, J. M., Choi, M. K. & Kim, S. B. Perioperative results and complications after posterior lumbar interbody fusion for spinal stenosis in geriatric patients over than 70 years old. J. Korean Neurosurg. Soc. 60, 684–690. https://doi.org/10.3340/jkns.2017.0203 (2017).
- McKillop, A. B., Carroll, L. J. & Battie, M. C. Depression as a prognostic factor of lumbar spinal stenosis: A systematic review. Spine J. 14, 837–846. https://doi.org/10.1016/j.spinee.2013.09.052 (2014).
- Heikkinen, J. et al. Depressive disorders, anxiety disorders and subjective mental health in common musculoskeletal diseases: A review. Maturitas 127, 18–25. https://doi.org/10.1016/j.maturitas.2019.05.011 (2019).
- Carreon, L. Y. et al. Can the anxiety domain of EQ-5D and mental health items from SF-36 help predict outcomes after surgery for lumbar degenerative disorders? J. Neurosurg. Spine 25, 352–356. https://doi.org/10.3171/2016.2.spine151472 (2016).
- Cinelli, C. & Hazlett, C. Making sense of sensitivity: Extending omitted variable bias. J. R. Stat. Soc. Ser. B (Stat. Methodol.) 82, 39–67. https://doi.org/10.1111/rssb.12348 (2020).
- 17. Held, U. *et al.* What is the treatment effect of surgery compared with nonoperative treatment in patients with lumbar spinal stenosis at 1-year follow-up? *J. Neurosurg. Spine.* https://doi.org/10.3171/2019.1.spine181098 (2019).
- Held, U. *et al.* Prognostic function to estimate the probability of meaningful clinical improvement after surgery—Results of a prospective multicenter observational cohort study on patients with lumbar spinal stenosis. *PLoS ONE* 13, e0207126. https://doi. org/10.1371/journal.pone.0207126 (2018).
- Steurer, J. et al. LumbSten: The lumbar spinal stenosis outcome study. BMC Musculoskelet. Dis. 11, 254. https://doi.org/10.1186/ 1471-2474-11-254 (2010).
- von Elm, E. et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet (London) 370, 1453–1457. https://doi.org/10.1016/s0140-6736(07)61602-x (2007).
- 21. Bjelland, I., Dahl, A. A., Haug, T. T. & Neckelmann, D. The validity of the hospital anxiety and depression scale. An updated literature review. J. Psychosom. Res. 52, 69–77 (2002).
- 22. Zigmond, A. S. & Snaith, R. P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67, 361–370 (1983).
- Ulrich, N. H. *et al.* The impact of incidental durotomy on the outcome of decompression surgery in degenerative lumbar spinal canal stenosis: Analysis of the Lumbar Spinal Outcome Study (LSOS) data—A Swiss prospective multi-center cohort study. *BMC Musculoskelet. Disord.* 17, 170. https://doi.org/10.1186/s12891-016-1022-y (2016).
- 24. Stucki, G. *et al.* Measurement properties of a self-administered outcome measure in lumbar spinal stenosis. *Spine* **21**, 796–803 (1996).
- Wertli, M. M., Steurer, J., Wildi, L. M. & Held, U. Cross-cultural adaptation of the German version of the spinal stenosis measure. *Eur. Spine J.* 23, 1309–1319. https://doi.org/10.1007/s00586-014-3245-7 (2014).
- 26. Salvi, F. et al. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J. Am. Geriatr. Soc. 56, 1926–1931 (2008).
- 27. R Core Team R: A language and environment for statistical computing. In *R Foundation for Statistical Computing* (ed. Core Team, R.) (R Core Team, 2021).
- Lebow, R. *et al.* Microdiscectomy improves pain-associated depression, somatic anxiety, and mental well-being in patients with herniated lumbar disc. *Neurosurgery* 70, 306–311. https://doi.org/10.1227/NEU.0b013e3182302ec3 (2012).
- Falavigna, A. et al. Responsiveness of depression and its influence on surgical outcomes of lumbar degenerative diseases. Eur. J. Orthop. Surg. Traumatol. 25(Suppl 1), S35–S41. https://doi.org/10.1007/s00590-015-1651-0 (2015).
- Havakeshian, S. & Mannion, A. F. Negative beliefs and psychological disturbance in spine surgery patients: A cause or consequence of a poor treatment outcome? *Eur. Spine J.* 22, 2827–2835. https://doi.org/10.1007/s00586-013-2822-5 (2013).
- 31. Sinikallio, S. *et al.* Life dissatisfaction is associated with a poorer surgery outcome and depression among lumbar spinal stenosis patients: A 2-year prospective study. *Eur. Spine J.* **18**, 1187–1193. https://doi.org/10.1007/s00586-009-0955-3 (2009).
- 32. Sinikallio, S. *et al.* Depression is associated with a poorer outcome of lumbar spinal stenosis surgery: A two-year prospective follow-up study. *Spine* **36**, 677–682. https://doi.org/10.1097/BRS.0b013e3181dcaf4a (2011).
- Pakarinen, M. et al. Life dissatisfaction is associated with depression and poorer surgical outcomes among lumbar spinal stenosis patients: A 10-year follow-up study. Int. J. Rehabil. Res. https://doi.org/10.1097/mrr.00000000000182 (2016).
- Theunissen, M., Peters, M. L., Bruce, J., Gramke, H. F. & Marcus, M. A. Preoperative anxiety and catastrophizing: A systematic review and meta-analysis of the association with chronic postsurgical pain. *Clin. J. Pain* 28, 819–841. https://doi.org/10.1097/AJP. 0b013e31824549d6 (2012).
- de Groot, K. I. *et al.* The influence of psychological variables on postoperative anxiety and physical complaints in patients undergoing lumbar surgery. *Pain* 69, 19–25. https://doi.org/10.1016/s0304-3959(96)03228-9 (1997).
- 36. Vlaeyen, J. W. & Linton, S. J. Are we "fear-avoidant"? Pain 124, 240-241. https://doi.org/10.1016/j.pain.2006.06.031 (2006).
- Pincus, T., Smeets, R. J., Simmonds, M. J. & Sullivan, M. J. The fear avoidance model disentangled: Improving the clinical utility of the fear avoidance model. *Clin. J. Pain* 26, 739–746. https://doi.org/10.1097/AJP.0b013e3181f15d45 (2010).
- Wertli, M. M. et al. Fear-avoidance beliefs-a moderator of treatment efficacy in patients with low back pain: A systematic review. Spine J. 14, 2658–2678. https://doi.org/10.1016/j.spinee.2014.02.033 (2014).
- Wertli, M. M. et al. Catastrophizing a prognostic factor for outcome in patients with low back pain: A systematic review. Spine J. 14, 2639–2657. https://doi.org/10.1016/j.spinee.2014.03.003 (2014).

- Wertli, M. M., Rasmussen-Barr, E., Weiser, S., Bachmann, L. M. & Brunner, F. The role of fear avoidance beliefs as a prognostic factor for outcome in patients with nonspecific low back pain: A systematic review. *Spine J.* 14, 816–836. https://doi.org/10.1016/j. spinee.2013.09.036 (2014).
- Burgstaller, J. M. *et al.* The influence of pre- and postoperative fear avoidance beliefs on postoperative pain and disability in patients with lumbar spinal stenosis: Analysis of the Lumbar Spinal Outcome Study (LSOS) Data. *Spine* 42, E425–E432. https://doi.org/10. 1097/BRS.00000000001845 (2017).
- Archer, K. R., Seebach, C. L., Mathis, S. L., Riley, L. H. 3rd. & Wegener, S. T. Early postoperative fear of movement predicts pain, disability, and physical health six months after spinal surgery for degenerative conditions. *Spine J.* 14, 759–767. https://doi.org/10. 1016/j.spinee.2013.06.087 (2014).
- Starkweather, A. R., Witek-Janusek, L., Nockels, R. P., Peterson, J. & Mathews, H. L. Immune function, pain, and psychological stress in patients undergoing spinal surgery. Spine 31, E641–E647. https://doi.org/10.1097/01.brs.0000231795.85409.87 (2006).

Author contributions

J.S., M.W. and U.H. designed the study. J.B. and G.P. were responsible for data management and data extraction. J.B., U.H. and M.D. were responsible for data analysis. M.W., J.B. and U.H. wrote the first draft of the manuscript. All authors read and approved the final manuscript.

Funding

The funding was provided by Helmut Horten Stiftung, Baugarten Foundation, OPO-Foundations, Stiftung Symphasis and also by Pfizer-Foundation for geriatrics and research in geriatrics.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/ 10.1038/s41598-022-06797-1.

Correspondence and requests for materials should be addressed to M.M.W.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022